基本資料/Profiles

實驗室研究方向: 一、口腔癌的治療及結合中草藥改善治療後產生潰瘍之狀況。 目前口腔癌的復發及抗藥性是影響口腔癌治療成功的關鍵，口腔癌五年存活率可達80%以上，但若有淋巴結轉移的患者則驟降50%左右，而發生遠端轉移則僅為20%上下。目前，口腔癌患者的治療方式，主要是手術、化療及放射性治療。一旦復發，醫師通常採取的治療方式為手術搭配輔助治療，目前唯一FDA認可使用的口腔癌標靶藥物為: Cetuximab (EGFR抑制劑)雖對大部分口腔癌病患有一定效果但仍然會因為長期使用而產生抗藥性。因此本實驗室目標為找出新的可能標的發展口腔癌標靶藥物。 我們使用RNA-seq分析了57位口腔癌臨床病人發現,當這些口腔癌病人有喝酒的行為或者其病灶已進入第三期(淋巴轉移),則有一個分泌蛋白(FGFBP1)表達特別高,FGFBP1為FGF-FGFR路徑的重要調控分子,因此我們進一步測試其功能並發展其單株抗體進行小鼠模式實驗,目前已取得初步結果。 為了解決口腔癌病患在化療及放療產生的口腔潰瘍(mucositis),我們建立了小鼠化療後潰瘍模式進一步篩選-中草藥, 目前初步篩選出幾種中草藥(例如Cibotium barometz)並將之萃取後進行體外體內之測試。 二、探討三陰性乳癌分泌之外泌體對於其治療的影響及機制。 三陰性乳癌目前是乳癌裡面標靶藥物最少且五年存活率最低的族群,因此本實驗進一步探討三陰性乳癌的復發及抗藥性之機制,我們藉由篩選出三陰性乳癌癌症幹細胞進一步探討及分析其重要的分子,並萃取其三陰性乳癌分泌之外泌體我們發現EDIL3這個分泌蛋白大量表達,並且藉由細胞及小鼠模式證實,含有EDIL3的外泌體會促使三陰性乳癌轉移及抗藥性增加,進一步我們也發展出EDIL3單株抗體,進一步來結抗癌細胞所分泌之外泌體對於周圍細胞之影響及探討其機制。 Research Directions: 1. Oral Cancer Treatment and the Use of Traditional Chinese Medicine to Improve Post-Treatment Ulceration Oral cancer recurrence and drug resistance are significant challenges to successful treatment. While the five-year survival rate for oral cancer patients can exceed 80%, it drops to approximately 50% for those with lymph node metastasis and further decreases to around 20% for patients with distant metastasis. Current treatments include surgery, chemotherapy, and radiation therapy. For recurrent cases, surgery combined with adjuvant therapy is often employed. Cetuximab, the only FDA-approved targeted drug for oral cancer, while effective for many patients, can lead to drug resistance with prolonged use. Our laboratory aims to identify novel targets for developing targeted therapies for oral cancer. Through RNA-seq analysis of 57 oral cancer patients, we discovered that the expression of a secretory protein, FGFBP1, was significantly elevated in patients with a history of alcohol consumption or tumors in the third stage (lymph node metastasis). FGFBP1 is a crucial regulator of the FGF-FGFR pathway. We have further investigated its function and developed monoclonal antibodies for mouse model experiments, and preliminary results have been obtained. To address oral mucositis induced by chemotherapy and radiotherapy in oral cancer patients, we established a mouse model of chemotherapy-induced ulceration and screened traditional Chinese medicine. Several herbs, such as Cibotium barometz, have been preliminarily identified and are being tested in vitro and in vivo. 2. Investigating the Impact and Mechanism of Exosomes Secreted by Triple-Negative Breast Cancer on Treatment Triple-negative breast cancer has the fewest available targeted therapies and the lowest five-year survival rate among breast cancer subtypes. To investigate the mechanisms of recurrence and drug resistance in triple-negative breast cancer, we have isolated cancer stem cells from triple-negative breast cancer and analyzed their key molecules. We found that the secretory protein EDIL3 is highly expressed in exosomes secreted by triple-negative breast cancer cells. Through cellular and mouse model experiments, we have confirmed that exosomes containing EDIL3 promote metastasis and increase drug resistance in triple-negative breast cancer. Furthermore, we have developed monoclonal antibodies against EDIL3 to further investigate the impact of exosomes secreted by cancer cells on surrounding cells and explore the underlying mechanisms.

中醫學院中西醫結合研究所 助理教授／Graduate Institute of Integrated Medicine Assistant Professor

基本資料/Profiles

學歷/Education

  • 中央大學 生命科學系 碩士
  • 中央大學 生命科學系分子醫學組 博士

經歷/Work experience

  • 國家衛生研究院分子與基因醫學研究所 博士後研究(1040801~1070630)
  • 中國醫藥大學中西醫結合研究所 博士後研究(1070701~1090731)
  • 中國醫藥大學中西醫結合研究所 專案助理教授(1090801~)

主管經歷/Administrative experience

專長/Research expertise

  • 基因調控
  • 訊息傳遞
  • 癌症幹細胞
  • 中草藥化合物與癌症幹細胞之拮抗
  • 單株抗體